Efficacy of secukinumab in treating psoriasis

The interleukin-17A (IL-17A) inhibitor secukinumab shows promise as a treatment option for patients with moderate to severe psoriasis

Researchers evaluated secukinumab in two phase III, double-blind 52-week trials, with 738 patients in the ERASURE study and 1,306 patients in the FIXTURE study.

Patients were randomly assigned to subcutaneous secukinumab at a dose of 300mg or 150mg, or placebo, or, in the FIXTURE study, 50mg etanercept.

About 80% of patients treated with 300mg secukinumab achieved PASI 75 at week 12, compared with 67-71.6% of those treated with 150mg secukinumab, and 44% of those treated with etanercept.

Secukinumab was found to clear skin more quickly than etanercept, with an average 50% reduction in affected skin and severity of psoriasis after three weeks compared with seven weeks with etanercept.

The incidence of side-effects in patients treated with secukinumab was comparable with those in patients treated with etanercept.

Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. New Engl J Med 2014; 371: 326-38

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more